Work

Outcome of Kidney Transplant Patients Following Treatment with Checkpoint Inhibitors: A Case Series

Year: 2025

Type: article

Abstract: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing immune surveillance against tumors. However, their use in kidney transplant recipients presents a significant challenge due to the risk of immune-mediated graft rejection. This retrospective case series highlights four kidney transplant recipients treated with ICIs for various malignancies, revealing the complex interplay between oncologic outcomes and transplant function. Two of four patients developed severe acute kidney injury (AKI), leading to dialysis-dependent graft loss despite high-dose corticosteroid therapy. One patient exhibited partial renal recovery following transient dialysis. In contrast, another patient maintained stable graft function despite prolonged ICI therapy. Oncologic outcomes varied, with two patients achieving significant tumor regression, while others experienced disease progression. These cases underscore the need for careful immunosuppressive management and close monitoring when administering ICIs in transplant recipients. The findings emphasize the importance of individualized treatment strategies to optimize both cancer control and graft survival.

Source: ASIDE Case Reports

DOI: 10.71079/aside.cr.08292549

Authors: Ahmed I Kamal, Mohmed Reyad, Menna Keshk, Ahmed Daoud, Sakshi Vaishnav, Munsef Barakat, Aurora Salas, Mahmoud Nassar, Karim Soliman

Institutions: Medical University of South Carolina, University of Arizona, University of Arizona College of Medicine- Phoenix, Cairo University, University of Vermont, University of Pittsburgh, University of Pittsburgh Medical Center

Language: English

Topic: Renal Transplantation Outcomes and Treatments

Subfield: Transplantation

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4413838759

FWCI:

Cites: 11

Cited by:

Related to: 10